Staphylococcus aureus bacteraemia: does duration matter?

[1]  Á. Soriano,et al.  Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. , 2020, The Lancet. Infectious diseases.

[2]  V. Nizet,et al.  IL-1β and IL-10 Host Responses in Patients with Staphylococcus aureus Bacteremia Determined by Antimicrobial Therapy. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  A. Ralph,et al.  Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial. , 2020, JAMA.

[4]  Rosemary C. She,et al.  Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  F. Ruffin,et al.  A Prognostic Model of Persistent Bacteremia and Mortality in Complicated Staphylococcus aureus Bloodstream Infection. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Scott A. Prentice,et al.  Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial , 2017 .

[7]  C. Woods,et al.  Clinical identifiers of complicated Staphylococcus aureus bacteremia. , 2003, Archives of internal medicine.

[8]  M. Sande,et al.  Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. , 1982, Annals of internal medicine.

[9]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.